Close Menu
    Beijing ScoopBeijing Scoop
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Beijing ScoopBeijing Scoop
    Home » Breakthrough in cell regeneration offers new hope for diabetes
    Health

    Breakthrough in cell regeneration offers new hope for diabetes

    January 10, 2024
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    In a groundbreaking development, researchers have discovered a method to regenerate insulin-producing cells in the pancreas, potentially revolutionizing diabetes treatment. This breakthrough, spearheaded by the Baker Heart and Diabetes Institute in Australia, involves repurposing FDA-approved drugs to stimulate the growth of pancreatic ductal progenitor cells, which can mimic the function of β-cells typically impaired in type 1 diabetes.

    Breakthrough in cell regeneration offers new hope for diabetes

    The study centers on two drugs, GSK126 and Tazemetostat, originally approved for cancer treatments. These drugs target the EZH2 enzyme, a key regulator of cell development, and by inhibiting this enzyme, the researchers were able to reprogram pancreatic ductal cells to produce and secrete insulin in response to glucose levels, akin to β-cells. This discovery is particularly significant for type 1 diabetes, where the immune system erroneously destroys β-cells, necessitating regular insulin injections to manage blood glucose levels.

    The research revealed that it only took 48 hours of drug-induced stimulation for regular insulin production to resume in tissue samples from individuals with and without diabetes, spanning various ages. Given the global prevalence of diabetes, affecting approximately 422 million people, this innovative approach offers a potential alternative to the constant monitoring and management of blood sugar levels. However, the research is still in its early stages, with clinical trials yet to commence.

    This advancement is not isolated; it forms part of a broader spectrum of scientific explorations into diabetes treatment, including new drug developments and strategies to protect insulin-producing cells before their destruction. Epigeneticist Sam El-Osta, from the Baker Heart and Diabetes Institute, highlights the importance of this regenerative approach for future clinical applications, emphasizing the need to understand the epigenetic mechanisms driving such regeneration in humans. The full details of this research have been published in Signal Transduction and Targeted Therapy.

    Related Posts

    Guinea ends mpox outbreak more than two years after first case

    November 21, 2026

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026

    Ebola cases top 11,200 as Africa CDC warns of record outbreak

    November 16, 2026

    Yellow fever kills 18 across nine African nations, WHO says

    November 7, 2026

    Dengue kills 173 in October as Bangladesh toll climbs to 418

    November 2, 2026

    Ebola deaths in DR Congo reach 5,340, fatality rate at 51.6%

    November 2, 2026
    Latest News

    Guinea ends mpox outbreak more than two years after first case

    November 21, 2026

    WFP warns funding gaps will leave millions hungry in 2027

    November 21, 2026

    South Korea’s exports pass $1 trillion for the first time

    November 21, 2026

    Air Arabia Egypt launches Cairo to Al Ain flights soon

    November 20, 2026

    Botswana opens consultations on proposed 33 percent hike now

    November 19, 2026

    PM Modi meets Prince and Princess of Wales for climate talks

    November 19, 2026

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026
    © 2026 Beijing Scoop | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.